Bedfont Scientific Ltd. will be celebrating the 10th birthday of its NObreath® FeNO monitor at the 2017 European Respiratory Society (ERS) Congress.
Regarded as the largest gathering of respiratory professionals worldwide, this year the ERS will be congregating in Milan between 9-13th September. Medical device manufacturer, Bedfont will be hosting a competition at the event where one lucky participant can win their very own monitor. Entrants simply have to take a NObreath FeNO test and have their photo taken with their FeNO reading to be included in the prize draw.
Using FeNO measurements to evaluate airway inflammation in asthma represents a significant advance in respiratory medicine, but until now it has been an expensive test to deliver in everyday practice. Recommended by NICE and conformed to ERS/ATS guidelines, the NObreath FeNO monitor is the essential tool for asthma.
Jason Smith, General Manager at Bedfont Scientific, explains, “Nitric Oxide is naturally produced by the lungs to combat airway inflammation, therefore FeNO levels are higher in people with asthma and, by measuring these levels during diagnosis and management of the disease, it can improve basic asthma care. By using the NObreath FeNO monitor in basic asthma care, the GP will be able to not only determine the type of asthma (allergic or non-allergic) allowing the correct medication to be prescribed but also differentiate between asthma and other respiratory conditions. Furthermore, the NObreath shows patient adherence to medicine allowing GP’s to adjust and prescribe the level of medication as necessary. We are proud to have spent the past 10 years perfecting FeNO monitoring to be able to provide not only an affordable technology but also a quick, easy and non-invasive procedure for both the GP and the patient, to improve asthma management.”